Headquartered in Chattanooga, TN, CBL Properties owns and manages a national portfolio of market-dominant properties located in dynamic and growing communities. CBL's owned and managed portfolio is comprised of 94 properties totaling 58.5 million square feet across 22 states, including 56 high-quality enclosed malls, outlet centers and lifestyle retail centers as well as more than 30 open-air centers and other assets. CBL seeks to continuously strengthen its company and portfolio through active management, aggressive leasing and profitable reinvestment in its properties.

CBL & Associates Properties Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ceribell, Inc. (CBLL – Research Report) and Cochle...

Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and Cochlear (OtherCHEOF)

Kepler Capital analyst Thomas Renaud maintained a Buy rating on MERSEN on January 27 and set a price target of €31.00. The company’s shares closed ...

Kepler Capital  Keeps Their Buy Rating on MERSEN (0Q6Q)

An update from Control Bionics Ltd. ( ($AU:CBL) ) is now available. Control Bionics has signed a two-year US distribution agreement with AAC specia...

Control Bionics Secures PRC-Saltillo Deal to Expand NeuroNode Access in US

PCBL Chemical Limited ( ($IN:PCBL) ) has issued an announcement. PCBL Chemical Limited has announced that its wholly owned subsidiary, PCBL (TN) Li...

PCBL Chemical Starts Commercial Production on New Carbon Black Line in Tamil Nadu

Clear Blue Technologies International ( ($TSE:CBLU) ) has issued an update. Clear Blue Technologies International has applied to the TSX Venture Ex...

Clear Blue Technologies Expands Private Placement to Raise Up to $1.2 Million

In a report released on January 6, Thomas Renaud from Kepler Capital maintained a Buy rating on MERSEN, with a price target of €31.00. The company’...

Kepler Capital  Remains a Buy on MERSEN (0Q6Q)

Ceribell, Inc. ( ($CBLL) ) has issued an announcement. On January 5, 2026, Ceribell announced that the U.S. Food and Drug Administration granted Br...

Ceribell Wins FDA Breakthrough Status for LVO Stroke Tool

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ceribell, Inc. (CBLL – Research Report) and Evommune...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CBL	$36.31	-1.05%	111.83K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CBL	$36.31	-1.0%	111.83K
3
4
5
6

CBL

CBL

Compare Stocks

Start Your Comparison

Get CBL & Associates Properties Inc. Data in Excel

Get CBL & Associates Properties Inc. Data in Excel